Published in Infect Immun on October 01, 1990
Innate immunity to Mycobacterium tuberculosis. Clin Microbiol Rev (2002) 2.79
Mechanisms of stimulation of interleukin-1 beta and tumor necrosis factor-alpha by Mycobacterium tuberculosis components. J Clin Invest (1993) 2.38
Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production. Proc Natl Acad Sci U S A (1996) 2.15
Analysis of the local kinetics and localization of interleukin-1 alpha, tumour necrosis factor-alpha and transforming growth factor-beta, during the course of experimental pulmonary tuberculosis. Immunology (1997) 1.95
Enhanced interleukin-8 release and gene expression in macrophages after exposure to Mycobacterium tuberculosis and its components. J Clin Invest (1995) 1.85
Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptional activation at the long terminal repeat. J Clin Invest (1995) 1.68
Increase in tumor necrosis factor alpha- and interleukin-6-secreting cells in peripheral blood mononuclear cells from subjects infected with Mycobacterium tuberculosis. Infect Immun (1991) 1.67
Effect of Mycobacterium tuberculosis and its components on macrophages and the release of matrix metalloproteinases. Thorax (1996) 1.61
Tumor necrosis factor production in patients with leprosy. Infect Immun (1992) 1.55
Activation of the interleukin 6 gene by Mycobacterium tuberculosis or lipopolysaccharide is mediated by nuclear factors NF-IL6 and NF-kappa B. Proc Natl Acad Sci U S A (1994) 1.50
Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med (1995) 1.46
Regulation of the interleukin-1 beta (IL-1 beta) gene by mycobacterial components and lipopolysaccharide is mediated by two nuclear factor-IL6 motifs. Mol Cell Biol (1993) 1.28
Tumor necrosis factor alpha (TNFalpha) promotes growth of virulent Mycobacterium tuberculosis in human monocytes iron-mediated growth suppression is correlated with decreased release of TNFalpha from iron-treated infected monocytes. J Clin Invest (1997) 1.20
Production of interleukin-10 and transforming growth factor beta by peripheral blood mononuclear cells in Q fever endocarditis. Infect Immun (1996) 1.18
Cytokine gene expression by cultures of human lymphocytes with autologous Mycobacterium tuberculosis-infected monocytes. Infect Immun (1994) 1.17
T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB). Clin Exp Immunol (2000) 1.17
Inhibition of ex vivo proinflammatory cytokine secretion in fatal Mycobacterium tuberculosis infection. Clin Exp Immunol (1995) 1.16
The effect of Mycobacterium tuberculosis on the susceptibility of human cells to the stimulatory and toxic effects of tumour necrosis factor. Immunology (1992) 1.16
Role of tumor necrosis factor-alpha in the spontaneous development of pulmonary fibrosis in viable motheaten mutant mice. Am J Pathol (1997) 1.15
Lipoarabinomannans derived from different strains of Mycobacterium tuberculosis differentially stimulate the activation of NF-kappa B and KBF1 in murine macrophages. Infect Immun (1995) 1.14
Early activation of splenic macrophages by tumor necrosis factor alpha is important in determining the outcome of experimental histoplasmosis in mice. Infect Immun (1992) 1.08
Ineffective cellular immune response associated with T-cell apoptosis in susceptible Mycobacterium bovis BCG-infected mice. Infect Immun (2000) 0.99
Induction of monocyte expression of tumor necrosis factor alpha by the 30-kD alpha antigen of Mycobacterium tuberculosis and synergism with fibronectin. J Clin Invest (1996) 0.94
Effect of lipoarabinomannan and mycobacteria on tumour necrosis factor production by different populations of murine macrophages. Clin Exp Immunol (1993) 0.94
Identification by two-dimensional gel electrophoresis of a 58-kilodalton tumor necrosis factor-inducing protein of Mycobacterium tuberculosis. Infect Immun (1993) 0.93
Infection of human immunodeficiency virus 1 transgenic mice with Toxoplasma gondii stimulates proviral transcription in macrophages in vivo. J Exp Med (1996) 0.93
The production of tumour necrosis factor-alpha is decreased in peripheral blood mononuclear cells from multidrug-resistant tuberculosis patients following stimulation with the 30-kDa antigen of Mycobacterium tuberculosis. Clin Exp Immunol (2003) 0.90
Mycobacterial antigen complex A60-specific T-cell repertoire during the course of pulmonary tuberculosis. Infect Immun (1993) 0.90
Transfer factors as immunotherapy and supplement of chemotherapy in experimental pulmonary tuberculosis. Clin Exp Immunol (2004) 0.88
Discordance in CD4+T-cell levels and viral loads with co-occurrence of elevated peripheral TNF-α and IL-4 in newly diagnosed HIV-TB co-infected cases. PLoS One (2013) 0.83
Interferon-gamma and tumour necrosis factor-alpha production by CD4+ T and CD8+ T lymphocytes in AIDS patients with tuberculosis. Clin Exp Immunol (2005) 0.81
Correlation of serum tumor necrosis factor-alpha, interleukin-4 and soluble interleukin-2 receptor levels with radiologic and clinical manifestations in active pulmonary tuberculosis. Mediators Inflamm (2003) 0.81
Increased expression and occupancy of receptors for tumour necrosis factor on blood monocytes from tuberculosis patients. Clin Exp Immunol (1993) 0.80
Tumour Necrosis Factor-alpha Production and Immune Cell Activation in Tuberculous Meningitis. Mediators Inflamm (1994) 0.78
Immunological responses in patients with tuberculosis and in vivo effects of acetyl-L-carnitine oral administration. Mediators Inflamm (1993) 0.76
Enhancement of Mycobacterium tuberculosis-induced tumor necrosis factor alpha production from primary human monocytes by an activated T-cell membrane-mediated mechanism. Infect Immun (2001) 0.76
Immunoregulatory biological response modifiers: effect of cytokines on septic shock. Mediators Inflamm (1993) 0.75
An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 23.42
The influence of immunologically committed lymphoid cells on macrophage activity in vivo. J Exp Med (1969) 20.62
The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell (1989) 10.98
Secretory products of macrophages. J Clin Invest (1987) 10.33
A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods (1986) 8.88
Cachectin: more than a tumor necrosis factor. N Engl J Med (1987) 8.74
Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J Immunol (1988) 4.47
Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol (1989) 3.90
Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun (1988) 3.70
T cell dependence of macrophage activation and mobilization during infection with Mycobacterium tuberculosis. Infect Immun (1974) 3.16
Production of tumor necrosis factor during murine listeriosis. J Immunol (1987) 3.14
The role of gamma-interferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis. Immunology (1987) 2.91
Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides. J Immunol (1988) 2.58
Activity of recombinant tumor necrosis factor on Toxoplasma gondii and Trypanosoma cruzi. J Immunol (1986) 2.53
Expression of tumor necrosis factor in vitro by human mononuclear phagocytes stimulated with whole Mycobacterium bovis BCG and mycobacterial antigens. Infect Immun (1988) 2.21
Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. J Immunol (1989) 1.92
Fc-receptor cross-linking induces rapid secretion of tumor necrosis factor (cachectin) by human peripheral blood monocytes. J Immunol (1988) 1.51
Association between HLA-DR2 and production of tumour necrosis factor alpha and interleukin 1 by mononuclear cells activated by lipopolysaccharide. Scand J Immunol (1988) 1.37
Production of tumour necrosis factor and interleukin 1 by monocytes of patients with previous Yersinia arthritis. Clin Exp Immunol (1988) 1.16
Tumour necrosis factor production by IL-2-activated macrophages in vitro and in vivo. Immunology (1989) 1.00
Human T cells and interleukin 4 inhibit the release of interleukin 1 induced by lipopolysaccharide in serum-free cultures of autologous monocytes. Eur J Immunol (1989) 0.99
Spontaneous and stimulated release of tumor necrosis factor-alpha (TNF) from blood monocytes of miners with coal workers' pneumoconiosis. Am Rev Respir Dis (1988) 0.98
Recombinant human interleukin-2 reverses in vitro-deficient cell-mediated immune responses to tuberculin purified protein derivative by lymphocytes of tuberculous patients. Infect Immun (1987) 0.88
Macrophage functions in Biozzi mice. Immunology (1985) 0.83
Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature (1990) 5.15
A hepatitis B surface antigen polypeptide (P31) with the receptor for polymerized human as well as chimpanzee albumins. Gastroenterology (1983) 2.49
Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. Int J Clin Oncol (2001) 2.10
IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol (1988) 1.92
A polypeptide containing 55 amino acid residues coded by the pre-S region of hepatitis B virus deoxyribonucleic acid bears the receptor for polymerized human as well as chimpanzee albumins. Gastroenterology (1984) 1.90
p26 protein and 33-nm particle associated with nucleocapsid of hepatitis C virus recovered from the circulation of infected hosts. Virology (1992) 1.84
Age-related changes in the subsets and functions of human T lymphocytes. J Immunol (1978) 1.82
Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer (1989) 1.80
Age-related decline in the in vitro and in vivo syntheses of anti-tetanus toxoid antibody in humans. J Immunol (1980) 1.78
B cell growth factors and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. J Exp Med (1983) 1.73
Characterization of human B cell growth factor (BCGF) from cloned T cells or mitogen-stimulated T cells. J Immunol (1983) 1.57
Angiosarcoma of the scalp associated with renal transplantation. Br J Dermatol (1997) 1.51
Phosphorylation in the carboxyl-terminal domain of the capsid protein of hepatitis B virus: evaluation with a monoclonal antibody. J Virol (1991) 1.48
Histamine prevents apoptosis in human monocytes. Clin Exp Allergy (2007) 1.46
Multilineage differentiation of Cbfa1-deficient calvarial cells in vitro. Biochem Biophys Res Commun (2000) 1.45
Mutant fibronectin gene in skin fibroblasts of sclerotic lesions from patients with progressive systemic sclerosis. Arthritis Rheum (1989) 1.41
Digital subtraction high-frame-rate echocardiography in detecting delayed onset of regional left ventricular relaxation in ischemic heart disease. Circulation (1995) 1.39
Monoclonal anti-Fc epsilon receptor antibodies with different specificities and studies on the expression of Fc epsilon receptors on human B and T cells. J Immunol (1986) 1.39
IgE class-specific suppressor T cells and factors in humans. J Immunol (1983) 1.31
Functional V region formation during in vitro culture of a murine immature B precursor cell line. Nature (1983) 1.30
Differential regulation of formation of multinucleated giant cells from concanavalin A-stimulated human blood monocytes by IFN-gamma and IL-4. J Immunol (1993) 1.29
Elevation of serum interleukin 6 prior to acute phase proteins on the inflammation by surgical operation. Clin Immunol Immunopathol (1989) 1.26
Analysis of T cell subsets by monoclonal antibodies in patients with tuberculosis after in vitro stimulation with purified protein derivative of tuberculin. Clin Exp Immunol (1984) 1.25
Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia (2006) 1.24
Immunohistochemical demonstration of substance P-containing nerve fibres in glomus tumours. Br J Dermatol (1985) 1.23
Increase of gamma/delta T cells in hospital workers who are in close contact with tuberculosis patients. Infect Immun (1994) 1.22
Depressed immunological defence mechanisms in mice with experimentally induced diabetes. Infect Immun (1980) 1.18
Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? Biochem Biophys Res Commun (1998) 1.18
Dissociation in the production of B cell-stimulating factors (BCGF and BCDF) and interleukin 2 by T cells from a common variable immunodeficient patient. J Immunol (1984) 1.17
The immune response to hapten-azo bovine serum albumin as detected by hemolytic plaque technique. Int Arch Allergy Appl Immunol (1968) 1.17
Increase in T cells bearing IgG Fc receptors in peripheral blood of patients with tuberculosis by in vitro stimulation with purified protein derivative. Am Rev Respir Dis (1980) 1.16
Adjuvanticity of mycobacterial cell walls. Jpn J Microbiol (1971) 1.16
Age-related changes of heat shock protein gene transcription in human peripheral blood mononuclear cells. Biochem Biophys Res Commun (1988) 1.13
Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves. Arch Surg (2000) 1.12
2-Arachidonoylglycerol, a putative endogenous cannabinoid receptor ligand, induces rapid, transient elevation of intracellular free Ca2+ in neuroblastoma x glioma hybrid NG108-15 cells. Biochem Biophys Res Commun (1996) 1.10
Development of selective IgM deficiency in systemic lupus erythematosus patients with disease of long duration. Arthritis Rheum (1987) 1.10
Mycobacterium avium-Mycobacterium intracellular complex-induced suppression of T-cell proliferation in vitro by regulation of monocyte accessory cell activity. Infect Immun (1990) 1.10
A human helper T cell clone secreting both killer helper factor(s) and T cell-replacing factor(s). J Immunol (1982) 1.09
Distinction between suppressors of the delayed-type hypersensitivity and the humoral response to sheep erythrocytes. Immunology (1978) 1.09
Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta (1989) 1.08
The frequency in Japanese of genetic variants of 22 proteins II. Carbonic anhydrase I and II, lactate dehydrogenase, malate dehydrogenase, nucleoside phosphorylase, triose phosphate isomerase, haemoglobin A and haemoglobin A2. Ann Hum Genet (1977) 1.08
The frequency in Japanese of genetic variants of 22 proteins. III. Phosphoglucomutase-1, phosphoglucomutase-2, 6-phosphogluconate dehydrogenase, adenylate kinase, and adenosine deaminase. Ann Hum Genet (1977) 1.06
Copigmentation gives bluer flowers on transgenic torenia plants with the antisense dihydroflavonol-4-reductase gene. Plant Sci (2000) 1.06
Demonstration of a hepatitis C virus-specific antigen predicted from the putative core gene in the circulation of infected hosts. J Gen Virol (1992) 1.05
Relationship between the rearrangement of immunoglobulin genes, the appearance of a B lymphocyte antigen, and immunoglobulin synthesis in murine pre-B cell lines. J Immunol (1982) 1.05
Comparison of innervated and noninnervated free flaps in oral reconstruction. Plast Reconstr Surg (1999) 1.04
Interleukin-12 activates human gamma delta T cells: synergistic effect of tumor necrosis factor-alpha. Eur J Immunol (1996) 1.04
CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol (1992) 1.04
Occurrence of lysophosphatidic acid and its alkyl ether-linked analog in rat brain and comparison of their biological activities toward cultured neural cells. Biochim Biophys Acta (1999) 1.02
Clinical effectiveness of a new bronchodilator, inolin, on bronchial asthma. Ann Allergy (1968) 1.02
Enhanced expression of the tumour necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis. Clin Exp Immunol (1990) 1.02
Frequency of tuberculin-reactive T-lymphocytes in pleural fluid and blood from patients with tuberculous pleurisy. Chest (1986) 1.01
Effect of age and Helicobacter pylori infection on gastric acid secretion. J Gastroenterol Hepatol (2000) 1.01
A glycopeptide containing 15 amino acid residues derived from hepatitis B surface antigen particles: demonstration of immunogenicity to raise anti-HBs in mice. Mol Immunol (1982) 1.00
In vitro tuberculin reactivity of lymphocytes from patients with tuberculous pleurisy. Infect Immun (1982) 1.00
Synthesis of sulfazecin-type 2-azetidinones with a carbon substituent at the 4-position. J Antibiot (Tokyo) (1983) 1.00
Skin penetration enhancing action of cis-unsaturated fatty acids with omega-9, and omega-12-chain lengths. Biol Pharm Bull (1998) 1.00
Human helper T cell factor(s) (ThF). I. Partial purification and characterization. J Immunol (1981) 0.98
Immune responses in aged mice. Clin Exp Immunol (1969) 0.97
Intraosseous hemangioma of the vomer: a case report. Am J Rhinol (1998) 0.96
Chemical modification of fumagillin. I. 6-O-acyl, 6-O-sulfonyl, 6-O-alkyl, and 6-O-(N-substituted-carbamoyl)fumagillols. Chem Pharm Bull (Tokyo) (1992) 0.95
Protooncogene expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus as an indicator of the disease activity. Clin Immunol Immunopathol (1987) 0.95
Mechanisms of age-related decline in antigen-specific T cell proliferative response: IL-2 receptor expression and recombinant IL-2 induced proliferative response of purified Tac-positive T cells. Mech Ageing Dev (1986) 0.95
Molecular forms of motilin in the mammalian and human gut and human plasma. Gastroenterology (1981) 0.94
Estimation of D segment usage in initial D to JH joinings in a murine immature B cell line. Preferential usage of DFL16.1, the most 5' D segment and DQ52, the most JH-proximal D segment. J Immunol (1990) 0.94
Argon laser stapedotomy. Ann Otol Rhinol Laryngol (1982) 0.94
Depression of plasma gelsolin level during acute liver injury. Gastroenterology (1992) 0.93
Therapeutic RNA interference of malignant melanoma by electrotransfer of small interfering RNA targeting Mitf. Gene Ther (2006) 0.93
True carcinosarcoma of the maxillary sinus. Pathol Res Pract (1989) 0.92
Class-switching from mu to gamma 3 or gamma 2b production at pre-B cell stage. J Immunol (1986) 0.92
Tumour necrosis factor/cachectin plays a key role in autoimmune pulmonary inflammation in lupus-prone mice. Clin Exp Immunol (1991) 0.91
Age-related changes in suppressor functions of human T cells. J Immunol (1979) 0.91
Change of cell-mediated cytotoxicity with aging. J Immunol (1975) 0.91
Structure of the gene encoding the muscle-specific subunit of human phosphoglycerate mutase. J Biol Chem (1989) 0.91
Congenital malignant melanoma: a case report. Br J Dermatol (2004) 0.90
Inhibition of IgE production in B hybridomas by IgE class-specific suppressor factor from T hybridomas. J Immunol (1983) 0.90
Occlusion of small hepatic veins associated with systemic lupus erythematosus with the lupus anticoagulant and anti-cardiolipin antibody. Hepatogastroenterology (1989) 0.90
Superiority of minipool nucleic acid amplification technology for hepatitis B virus over chemiluminescence immunoassay for hepatitis B surface antigen screening. Vox Sang (2003) 0.89
Nonspecific recruitment of lymphocytes in purified protein derivative-induced lymphocyte proliferative response of patients with tuberculosis. Infect Immun (1982) 0.89
Enhanced expression of the heat shock protein gene in peripheral blood mononuclear cells of patients with active systemic lupus erythematosus. Ann Rheum Dis (1990) 0.88
Preferential and persistent activation of the STAT1 pathway in rheumatoid synovial fluid cells. J Rheumatol (2001) 0.88
Spatial and temporal expression of basic fibroblast growth factor protein during wound healing of rat skin. Br J Dermatol (2000) 0.88
Recombinant human interleukin-2 reverses in vitro-deficient cell-mediated immune responses to tuberculin purified protein derivative by lymphocytes of tuberculous patients. Infect Immun (1987) 0.88
Synchrotron X-ray imaging of the electron density in RFeO3 (R = Y, Ho) using an APD detector. J Synchrotron Radiat (1998) 0.88
Increase in rosette-forming T cells with autologous human erythrocytes in lymphocytes of patients with tuberculosis by in vitro stimulation with purified protein derivative. Int Arch Allergy Appl Immunol (1982) 0.88
Increase of T-cell receptor gamma/delta-bearing T cells in cord blood of newborn babies obtained by in vitro stimulation with mycobacterial cord factor. Infect Immun (1991) 0.87
Effect of serotonin on the differentiation of human monocytes into dendritic cells. Clin Exp Immunol (2006) 0.87
Tuberculin purified protein derivative-reactive T cells in cord blood lymphocytes. Infect Immun (1981) 0.87
Cutaneous metastasis from hepatocellular carcinoma resembling granuloma teleangiectaticum. J Dermatol (1989) 0.87